Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation. 2024

Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
Experimental Therapeutics in Lymphoid Malignancies Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical behavior. In 5-10% of patients the disease transforms into a diffuse large-B cell lymphoma known as Richter transformation (RT), which is associated with dismal prognosis. Here, we aimed to establish patient-derived xenograft (PDX) models to study the molecular features and evolution of CLL and RT. We generated two PDXs by injecting CLL (PDX12) and RT (PDX19) cells into immunocompromised NSG mice. Both PDXs were morphologically and phenotypically similar to RT. Whole-genome sequencing analysis at different time points of the PDX evolution revealed a genomic landscape similar to RT tumors from both patients and uncovered an unprecedented RT subclonal heterogeneity and clonal evolution during PDX generation. In PDX12, the transformed cells expanded from a very small subclone already present at the CLL stage. Transcriptomic analysis of PDXs showed a high oxidative phosphorylation (OXPHOS) and low B-cell receptor (BCR) signaling similar to the RT in the patients. IACS-010759, an OXPHOS inhibitor, reduced proliferation, and circumvented resistance to venetoclax. In summary, we have generated new RT-PDX models, one of them from CLL cells that mimicked the evolution of CLL to RT uncovering intrinsic features of RT cells of therapeutical value.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015451 Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease. B-Cell Leukemia, Chronic,B-Lymphocytic Leukemia, Chronic,Chronic Lymphocytic Leukemia,Leukemia, B-Cell, Chronic,Leukemia, Lymphocytic, Chronic,Lymphocytic Leukemia, Chronic, B-Cell,Lymphoma, Small Lymphocytic,B-Cell Chronic Lymphocytic Leukemia,B-Cell Malignancy, Low-Grade,Diffuse Well-Differentiated Lymphocytic Lymphoma,Disrupted In B-Cell Malignancy,Leukemia, B Cell, Chronic,Leukemia, Chronic Lymphatic,Leukemia, Chronic Lymphocytic,Leukemia, Chronic Lymphocytic, B-Cell,Leukemia, Lymphoblastic, Chronic,Leukemia, Lymphocytic, Chronic, B Cell,Lymphoblastic Leukemia, Chronic,Lymphocytic Leukemia, Chronic,Lymphocytic Leukemia, Chronic, B Cell,Lymphocytic Lymphoma,Lymphocytic Lymphoma, Diffuse, Well Differentiated,Lymphocytic Lymphoma, Diffuse, Well-Differentiated,Lymphocytic Lymphoma, Well Differentiated,Lymphocytic Lymphoma, Well-Differentiated,Lymphoma, Lymphocytic,Lymphoma, Lymphocytic, Diffuse, Well Differentiated,Lymphoma, Lymphocytic, Diffuse, Well-Differentiated,Lymphoma, Lymphocytic, Well Differentiated,Lymphoma, Lymphocytic, Well-Differentiated,Lymphoma, Lymphoplasmacytoid, CLL,Lymphoma, Small Lymphocytic, Plasmacytoid,Lymphoma, Small-Cell,Lymphoplasmacytoid Lymphoma, CLL,Small-Cell Lymphoma,B Cell Chronic Lymphocytic Leukemia,B Cell Leukemia, Chronic,B Cell Malignancy, Low Grade,B Lymphocytic Leukemia, Chronic,B-Cell Leukemias, Chronic,B-Cell Malignancies, Low-Grade,B-Lymphocytic Leukemias, Chronic,CLL Lymphoplasmacytoid Lymphoma,CLL Lymphoplasmacytoid Lymphomas,Chronic B-Cell Leukemia,Chronic B-Cell Leukemias,Chronic B-Lymphocytic Leukemia,Chronic B-Lymphocytic Leukemias,Chronic Lymphatic Leukemia,Chronic Lymphatic Leukemias,Chronic Lymphoblastic Leukemia,Chronic Lymphoblastic Leukemias,Chronic Lymphocytic Leukemias,Diffuse Well Differentiated Lymphocytic Lymphoma,Disrupted In B Cell Malignancy,Leukemia, Chronic B-Cell,Leukemia, Chronic B-Lymphocytic,Leukemias, Chronic B-Cell,Leukemias, Chronic B-Lymphocytic,Leukemias, Chronic Lymphatic,Leukemias, Chronic Lymphoblastic,Low-Grade B-Cell Malignancies,Low-Grade B-Cell Malignancy,Lymphatic Leukemia, Chronic,Lymphatic Leukemias, Chronic,Lymphoblastic Leukemias, Chronic,Lymphocytic Leukemias, Chronic,Lymphocytic Lymphoma, Small,Lymphocytic Lymphomas,Lymphocytic Lymphomas, Small,Lymphocytic Lymphomas, Well-Differentiated,Lymphoma, CLL Lymphoplasmacytoid,Lymphoma, Small Cell,Lymphoma, Well-Differentiated Lymphocytic,Lymphomas, CLL Lymphoplasmacytoid,Lymphomas, Lymphocytic,Lymphomas, Small Lymphocytic,Lymphomas, Small-Cell,Lymphomas, Well-Differentiated Lymphocytic,Lymphoplasmacytoid Lymphomas, CLL,Malignancies, Low-Grade B-Cell,Malignancy, Low-Grade B-Cell,Small Cell Lymphoma,Small Lymphocytic Lymphoma,Small Lymphocytic Lymphomas,Small-Cell Lymphomas,Well-Differentiated Lymphocytic Lymphoma,Well-Differentiated Lymphocytic Lymphomas
D016403 Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation. Diffuse Large B-Cell Lymphoma,Diffuse, Large B-Cell, Lymphoma,Histiocytic Lymphoma, Diffuse,Lymphoma, Histiocytic, Diffuse,Diffuse Large-Cell Lymphoma,Histiocytic Lymphoma,Large Lymphoid Lymphoma, Diffuse,Large-Cell Lymphoma, Diffuse,Lymphoma, Diffuse Large-Cell,Lymphoma, Histiocytic,Lymphoma, Large Cell, Diffuse,Lymphoma, Large Lymphoid, Diffuse,Lymphoma, Large-Cell, Diffuse,Diffuse Histiocytic Lymphoma,Diffuse Histiocytic Lymphomas,Diffuse Large B Cell Lymphoma,Diffuse Large Cell Lymphoma,Diffuse Large-Cell Lymphomas,Histiocytic Lymphomas,Large Cell Lymphoma, Diffuse,Lymphoma, Diffuse Histiocytic,Lymphoma, Diffuse Large Cell
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D060965 Clonal Evolution The process of accumulation of genetic and epigenetic changes over time in individual cells and the effect of the changes on CELL PROLIFERATION. Somatic Evolution,Evolution, Clonal,Evolution, Somatic
D064593 Heterografts Tissues, cells or organs transplanted between animals of different species. Xenografts,Heterograft,Xenograft

Related Publications

Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
July 2024, Hematological oncology,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
August 2023, Hematological oncology,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
February 2022, Clinical journal of oncology nursing,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
January 2022, Indian journal of pathology & microbiology,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
January 2013, Journal of clinical and experimental hematopathology : JCEH,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
October 2013, The Israel Medical Association journal : IMAJ,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
May 2011, Leukemia & lymphoma,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
October 2013, The Journal of experimental medicine,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
July 2022, Journal of the advanced practitioner in oncology,
Heribert Playa-Albinyana, and Fabian Arenas, and Romina Royo, and Ariadna Giró, and Irene López-Oreja, and Marta Aymerich, and Mònica López-Guerra, and Gerard Frigola, and Sílvia Beà, and Julio Delgado, and Pablo M Garcia-Roves, and Elías Campo, and Ferran Nadeu, and Dolors Colomer
January 2023, Nature medicine,
Copied contents to your clipboard!